Aragen commissions $3 million formulations manufacturing facility in Hyderabad
The facility, set up at an investment of $3 million, is located at the Mallapur Campus in Hyderabad and spans over 12,000 sq ft area.
According to the company, it is equipped to support the clinical manufacturing of a wide range of dosage forms, including oral solids, liquids, tablets, capsules, semisolids, topicals, and films.
Manni Kantipudi, CEO at Aragen Life Sciences, said: “We are thrilled to announce the commissioning of our new formulations manufacturing facility in Hyderabad. This state-of-the-art facility represents a major milestone in Aragen's journey, reinforcing our commitment to innovation and excellence.
“With this expansion, we can offer our customers an even broader range of services, from early-stage development to clinical manufacturing, all from a co-located facility. We look forward to leveraging these capabilities to support our customers' drug development needs, enabling them to bring life-changing medicines to patients worldwide."
Aragen has been offering Formulation R&D services from its 10,000 sq ft research facility since 2018. The setting up of the Formulation manufacturing facility is a forward integration strategy to further strengthen its overall position as a ‘one-stop solution provider’ for the life sciences industry.
The facility, the manufacturing partner said, boasts a wide range of formulation technologies, including wet granulation, roller compaction, film coating, spray drying, tableting, capsule filling, bottle filling, and blister packing.
In addition, it has been strategically designed for future expansion, with plans to add nano-milling and hot melt extrusion capabilities next year.
The center can also accommodate 1,000 to 100,000 doses for solid orals and 1 to 100 litres for liquids, managed by a team of approximately 60 staff members.
Aragen has been providing formulation R&D services at its 10,000 sq ft research facility since 2018. The new facility indicates a ‘strategic move’ to reinforce its position as a comprehensive 'one-stop solution provider' for the life sciences industry.
